OTCMKTS:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis $6.05 0.00 (0.00%) As of 11/13/2026 12:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Interpace Biosciences Stock (OTCMKTS:IDXG) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Interpace Biosciences alerts:Sign Up Key Stats Today's Range$6.05▼$6.1550-Day Range$4.95▼$8.5052-Week Range$4.95▼$7.45Volume441 shsAverage Volume1,539 shsMarket Capitalization$33.53 millionP/E Ratio15.13Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Interpace Biosciences is a molecular diagnostics company that develops and provides tests to help clinicians assess cancer risk and guide treatment decisions. Its services combine molecular analysis with pathology and related diagnostic expertise. The company’s tests focus on conditions including pancreatic cysts and thyroid nodules. Its offerings have included PancraGEN for pancreatic cyst assessment, as well as ThyGeNEXT and ThyraMIR for evaluating thyroid nodules. Interpace has also offered molecular testing for gastrointestinal cancers. Interpace Biosciences, formerly known as PDI, Inc., serves healthcare providers and patients primarily in the United States through its diagnostic testing services.AI Generated. May Contain Errors. Read More Interpace Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreIDXG MarketRank™: 0.91259298618 of 5 starsInterpace Biosciences scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Interpace Biosciences. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Interpace Biosciences is 15.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.37.Price to Earnings Ratio vs. SectorThe P/E ratio of Interpace Biosciences is 15.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.59.Price to Book Value per Share RatioInterpace Biosciences has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Interpace Biosciences has been sold short.Short Interest Ratio / Days to CoverInterpace Biosciences has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Interpace Biosciences has recently increased by 550.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInterpace Biosciences does not currently pay a dividend.Dividend GrowthInterpace Biosciences does not have a long track record of dividend growth. News and Social Media0.9 / 5News Sentiment-0.50 News SentimentInterpace Biosciences has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Interpace Biosciences this week, compared to 2 articles on an average week. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Interpace Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders0.93% of the stock of Interpace Biosciences is held by insiders.Percentage Held by Institutions5.73% of the stock of Interpace Biosciences is held by institutions.Read more about Interpace Biosciences' insider trading history. Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDXG Stock News HeadlinesPDI: High Yield, Persistent Risks, But I'm Staying InvestedNovember 13 at 8:31 AM | seekingalpha.comPDI Gold Outlines West African Gold Projects in Investor PresentationNovember 10, 2026 | tipranks.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 16 at 1:00 AM | Profits Run (Ad)Core Sampling Completed for İzmir Hospital Conversion ProjectNovember 10, 2026 | tipranks.comTAPDİ Oksijen Announces Nine-Month Consolidated Operating ReviewNovember 5, 2026 | tipranks.comTAPDİ Oksijen Releases September 2026 Consolidated Financial StatementsNovember 5, 2026 | tipranks.comTAPDİ Oksijen Approves Nine-Month Consolidated Financial ReportsNovember 5, 2026 | tipranks.comSkylark Raises A$20m With PDI Gold Strategic InvestmentNovember 1, 2026 | tipranks.comSee More Headlines IDXG Stock Analysis - Frequently Asked Questions How have IDXG shares performed this year? Interpace Biosciences' stock was trading at $6.1510 at the beginning of the year. Since then, IDXG stock has decreased by 1.6% and is now trading at $6.05. How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (OTCMKTS:IDXG) issued its quarterly earnings results on Monday, August, 10th. The business services provider reported $0.05 earnings per share for the quarter. The business services provider had revenue of $9.13 million for the quarter. Interpace Biosciences had a net margin of 67.64% and a trailing twelve-month return on equity of 145.40%. When did Interpace Biosciences' stock split? Shares of Interpace Biosciences reverse split before market open on Thursday, August 27th 2026.The 1-5 reverse split was announced on Thursday, August 27th 2026. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 27th 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Interpace Biosciences? Shares of IDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), Block (XYZ), Johnson & Johnson (JNJ) and NVIDIA (NVDA). Company Calendar Last Earnings8/10/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Healthcare Providers & Services Sub-IndustryHealthcare Services Current SymbolOTCMKTS:IDXG CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees102Year FoundedN/AProfitability EPS (Trailing Twelve Months)$0.40 Trailing P/E Ratio15.13 Forward P/E RatioN/A P/E GrowthN/ANet Income$24.58 million Net Margins67.64% Pretax Margin11.06% Return on Equity145.40% Return on Assets87.36% Debt Debt-to-Equity RatioN/A Current Ratio2.22 Quick Ratio2.22 Sales & Book Value Annual Sales$38.73 million Price / Sales0.87 Cash Flow$28.81 per share Price / Cash Flow0.21 Book Value$25.25 per share Price / Book0.24Miscellaneous Outstanding Shares5,542,000Free Float5,490,000Market Cap$33.53 million OptionableNot Optionable Beta0.67 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:IDXG) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment t...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.